{"name":"Endocyte","slug":"endocyte","ticker":"","exchange":"","domain":"","description":"Endocyte is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). As of 2013, the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis.","hq":"","founded":1996,"employees":"~93","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":70000,"revenueGrowth":483.3,"grossMargin":0,"rdSpend":25866845,"netIncome":-55064150,"cash":100762269,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"99mTc-Etarfolatide","genericName":"99mTc-Etarfolatide","slug":"99mtc-etarfolatide","indication":"Ovarian cancer","status":"phase_1"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ertafolide","genericName":"Ertafolide","slug":"ertafolide","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"99mTc-Etarfolatide","genericName":"99mTc-Etarfolatide","slug":"99mtc-etarfolatide","phase":"phase_1","mechanism":"binds to folate receptor beta","indications":["Ovarian cancer","Breast cancer"],"catalyst":""},{"name":"Ertafolide","genericName":"Ertafolide","slug":"ertafolide","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxNV3d4RDBVM3l2T2ZiNzBkdDJjSjRIckFGN2wzem1sck5XeEZzOFhYWVZKbFAybEZrY21YOU55cmx2cFB2bkpSbE90bEtBUFFldU40UVFTODhoRnptTXQyTE5LRkNpTjhJVHJ4RFNUamFyaXB1WWRqZ25pd3NHOTl5S1lPd0Y1ak92MlpMUE41WURGQnJ5SWVwZzFNUnlsRUxOclFyVzR1LXlmLU1tcE8wMjZtUm5pVnFON3ptdEdiR3lqSjBmNWR2WTljTml5LVdJRHhUcnJRUEhuLUF0NU1UYUExNm1VU0FkWHlWeFNRMkJLUC00ZDNaMHVFbHg2UWU5amRwZmZPRk02cDJSRzVhTFhaYzk4Zw?oc=5","date":"2025-04-29","type":"pipeline","source":"Purdue University","summary":"Blazing a new trail for early-stage innovation: Purdue announces creation of Low Institute for Therapeutics (LIFT) through a generous gift by Phil and Joan Low - Purdue University","headline":"Blazing a new trail for early-stage innovation: Purdue announces creation of Low Institute for Therapeutics (LIFT) throu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQaUpsVFdLQWhHa1VDV2RRSHhqUE5LRXFmemRZeHlUTUJPczZpOUQ3b0EweEx6em8wV3B3Z1VVakdrRk03U1d6VlhaampOajk1YVpUQzAzcHBTT2M5SDNSWFdHQkJxVzVObjVKWVh4Yk0wYVRjMWdiZXBIemJfNy1ncmlIU3dBeVVhSmNJVm80bWRIVHVOSXgzeGIwejBmdWJ2VExHcmMwX2IzdjFQdWRNT1prQUVteDhMNkxzTjh2TQ?oc=5","date":"2022-03-24","type":"regulatory","source":"Fierce Pharma","summary":"Novartis' radiotherapy Pluvicto nabs FDA approval for prostate cancer, with $2B-plus peak sales expectations - Fierce Pharma","headline":"Novartis' radiotherapy Pluvicto nabs FDA approval for prostate cancer, with $2B-plus peak sales expectations","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNOFN0U1pKRllvZEY1UFBJZ1h2VzFtdFI0eGtsS1N3VGlPZnZJYktwNWNXYmZIeGE3OFI5ZTdhNzVjRlJmX242VkQzYVNzZFpsRmd2NDE2MS04Uk95ZlJJTEhXaERvdXlCd2p1MnZLZnZlTUNEdVRodm9uOTYyRmRTZm9NSFE5RkxsRGJ2aVlNYWltNktyQU1uRTZQTEZLZENNY3RNWkMyOTVKWHZVeWNSWGpSeTk4cGY5UlJVd1JFRmZkX1B5?oc=5","date":"2020-06-25","type":"pipeline","source":"The ASCO Post","summary":"In Biochemically Recurrent Prostate Cancer, PSMA-Targeted PET/CT Imaging May Be Useful - The ASCO Post","headline":"In Biochemically Recurrent Prostate Cancer, PSMA-Targeted PET/CT Imaging May Be Useful","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOVC1PWV9jOUFzM1h2QTJWd3Q3dUxYNVRvdTlvdk1FWFZyQUtneXZnWWtTU3VGTmppSjhJTGR2dkFGM3k4WWNJakJpRW4tWE9tellEaEJSaXBDdlQ2UEFIV21YSDVENElHU2s2X3FVSnNUVlAxRWhkLWZxejktSGFEYlc4XzAtS1k?oc=5","date":"2018-10-19","type":"deal","source":"Pharmaceutical Technology","summary":"Novartis to acquire US cancer drug developer Endocyte for $2.1bn - Pharmaceutical Technology","headline":"Novartis to acquire US cancer drug developer Endocyte for $2.1bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxORDlsVzAzSlpLeEd5dmlXLXloUE1sMGQtQUllOGtDY25vdEF4U19iTlQ4UGY5QU82N3l1TzBsOV8xTThsWDAxVTJQSld5eVJ3SEFzaFpLajhyVHNqLXdsdFlRcUpWVTRFajNUdnJjX25aMENPbUpsbnN5UDhjRFZycW5KeFRxMkRxRmhxalIyc25wMm53NkVKNzVSWlVOM2pxdjhBR3RyZy1DZXJJZDFwUVp6X0Fsd1E?oc=5","date":"2018-10-18","type":"pipeline","source":"WFYI","summary":"West Lafayette-Based Endocyte Aquired For $2.1 Billion By Pharma Giant Novartis - WFYI","headline":"West Lafayette-Based Endocyte Aquired For $2.1 Billion By Pharma Giant Novartis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOdWFHbnJ5ZWZkZ18wN3hYNDNHVlhnUmJxMVZ0bEY5YnBTU2RwZ3BhaTBHX2pKSjZZd1F3OHhJaE5scHkzRng0QzRyemdDSXJqeHZZQjRkV2R5NUdvaVV0WGY1ZXFVdUtnMG4wRlBzdGVRZGluSTlHVGF6Q3Z6NWtzRlJPc0ZIX0VWZlQzNFloRG80NnJKdTlVbk5QaUN6N2lJNVFLd3hXQW5UUU9RZ3c?oc=5","date":"2018-10-18","type":"deal","source":"BioPharma Dive","summary":"Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan - BioPharma Dive","headline":"Novartis buys Endocyte for $2.1B in latest deal under CEO Narasimhan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNTgxRXJtN1VvZmMxWllvcjduUEVzYmhWNmtaOHAyTENsTm96aEZmcTEyTkVyUkJrZzcyNlIxVWxQX0xNWldORVNUWTNZSVU3dlpvaEtJc0d2OW82YXd3bTNJTkI2Rll6VTZlWlU0MTJwVDJsWnFXNGgzMjNWTWZFS0FsQlg0ZmtxVnpmZWVGRmstTFhuNmx3VnprUW5NV01fbGpIQ21TaUVHaUU?oc=5","date":"2018-10-18","type":"deal","source":"Journal & Courier","summary":"Purdue startup Endocyte sold in $2.1B deal with pharmaceutical giant Novartis - Journal & Courier","headline":"Purdue startup Endocyte sold in $2.1B deal with pharmaceutical giant Novartis - Journal & Courier","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFB0UjAxSHpHMkI1cDdJTS1jU0ZybGx5djZQM3Bub3FkZmRaSGw5T3kyb2ZhcDRLbVlRT2thYzlmSG5lN2lIWEJkT2RjZkZESUlwRVozTXBCSlF3MUNzWmlqNmRRSklsMEJNa3o3LU1Ud0c1Tk1RTDcyT3J3?oc=5","date":"2018-10-18","type":"pipeline","source":"BioSpace","summary":"Novartis Plunks Down $2.1 Billion for Endocyte - BioSpace","headline":"Novartis Plunks Down $2.1 Billion for Endocyte","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQbWVVTmREczNlU1dLTGs1SmJZNHBDYXdZMnBoSTV0bDhad2hNTWgxY1owRngxLXlZcVRzQ1VIa1dRU3Vmd241ME0xampLSFQ2VTZoeGdWNjBlUUJnT21UTzhwRUVBTUlCb0RoZ0M4dWp6T3lfSlM2SXQxVkZpWG1EbFAyT00tZlpQUTFBNDhNbFY1MmVCMFBaSHV5aEw3TFNtaUJj?oc=5","date":"2018-10-18","type":"deal","source":"Fierce Biotech","summary":"Novartis inks $2.1B Endocyte buyout, furthering radiotherapy push - Fierce Biotech","headline":"Novartis inks $2.1B Endocyte buyout, furthering radiotherapy push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQNFdmTF9ORS1GOE5hN0RWUDJNSHFqZllfOVhOTDcyUkQzRDU5TzlXQzFoQVdyRzNteHdtUWtzd2FNWDJtcXNLMUJiZW5MQWIwRHdiamN4RURZQTY4aWtFVkk1Z2d1LVJwb05nZEJLbUtUYkFnVzNLTXZZRmZkanJLTHY0ZmJlQUZMZWhVRXpCcE4zWmxOYm1zNkpvb21ERDg?oc=5","date":"2018-10-18","type":"deal","source":"WSJ","summary":"Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion - WSJ","headline":"Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPRGVoR2p1S21kaEFGMUxZYTJFeDhqb1d5c1ZJdVlZQ0FwMnRaeGM2UjlQcm5vOFFNX2dzV3pSTEV0VmtqM3hzeWpDRkNTTUlUSEVEblJ1d0RyZ0N2OV9DcXIwb1BneDIyOTYydHpBOF9kVkpKQlFPTTNlUWEyZ2xfVnk2c3NHQS03SzlB?oc=5","date":"2017-10-03","type":"deal","source":"pharmaphorum","summary":"Endocyte bounces back with late-stage prostate cancer deal - pharmaphorum","headline":"Endocyte bounces back with late-stage prostate cancer deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNUmdLOGt0X3VtN19tNl9jeEVSdkMwdVVJYVQwM3J2U0UzTWhjWkZiTjU4blJjdlM5X1F4YzluSkJUR1FNV2RSd2ItUWhOeWVqQURkTHltcnYtbzlRWG5YUkd5dE05MUFNS1lIMDJrUUJORENvWVdvNUJna1RQUjItZTFWMVE1dw?oc=5","date":"2017-06-06","type":"pipeline","source":"BioPharma Dive","summary":"Endocyte slumps on staff and R&D cuts - BioPharma Dive","headline":"Endocyte slumps on staff and R&D cuts","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":70000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":70000,"period":"2017-12-31"},{"value":12000,"period":"2017-12-31"},{"value":33000,"period":"2017-09-30"},{"value":13000,"period":"2017-06-30"},{"value":12000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":25866845,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-55064150,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":100762269,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}